Ipca Laboratories
Ipca Laboratories Limited, headquartered in Mumbai, India, is a prominent player in the pharmaceutical industry, specialising in the manufacture and export of active pharmaceutical ingredients (APIs) and finished dosage forms. Founded in 1949, the company has achieved significant milestones, including a robust presence in over 100 countries and a diverse product portfolio that encompasses a wide range of therapeutic areas such as cardiovascular, anti-infective, and pain management. With a commitment to quality and innovation, Ipca Laboratories stands out for its extensive range of generic formulations and APIs, which are produced in state-of-the-art facilities adhering to international standards. The company has garnered a strong market position, recognised for its consistent growth and contributions to healthcare, making it a trusted name in the global pharmaceutical landscape.
DitchCarbon Score
How does Ipca Laboratories's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ipca Laboratories's score of 21 is lower than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ipca Laboratories's reported carbon emissions
In 2024, Ipca Laboratories reported total carbon emissions of approximately 311,883,000 kg CO2e. This figure reflects the company's ongoing commitment to sustainability and climate action. In the previous year, 2023, the company disclosed emissions of about 311,883,000 kg CO2e, with Scope 1 emissions at approximately 174,538,000 kg CO2e and Scope 2 emissions at around 137,345,000 kg CO2e. In 2022, total emissions were about 326,556,000 kg CO2e, comprising approximately 124,880,000 kg CO2e from Scope 1 and about 179,114,000 kg CO2e from Scope 2. Ipca Laboratories has set an ambitious target to achieve a 20% reduction in carbon emissions by 2030, covering both Scope 1 and Scope 2 emissions. This target, initiated in 2022, underscores the company's proactive approach to mitigating its environmental impact. The company is currently on track to meet its near-term reduction goals. Overall, Ipca Laboratories is committed to enhancing its sustainability practices and reducing its carbon footprint, aligning with industry standards and climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 124,880,000 | 000,000,000 |
| Scope 2 | 179,114,000 | 000,000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ipca Laboratories is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
